Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IDP 023

Next Previous
Drug Profile

IDP 023

Alternative Names: IDP-023

Latest Information Update: 15 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Indapta Therapeutics
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; HLA antigen modulators; Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma
  • Phase I Multiple sclerosis
  • Preclinical Solid tumours

Most Recent Events

  • 30 Apr 2025 Indapta Therapeutics suspends phase I trial in Multiple sclerosis (Combination therapy, In adults, In the elderly) in USA (Parenteral) (NCT06677710)
  • 15 Jan 2025 Phase-I clinical trials in Multiple sclerosis (Combination therapy, In adults, In the elderly) in USA (Parenteral) (NCT06677710)
  • 17 Dec 2024 Indapta Therapeutics in collaboration with Stanford University and the University of California plans a phase I trial for Multiple sclerosis (Combination therapy) (Parenteral) in the first quarter of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top